A patient on chemotherapy with diffuse, non-scarring hair loss.

ANAGEN EFFLUVIUM or CHEMOTHERAPY-ASSOCIATED ALOPECIA

Anagen effluvium (AE) is the name for the common occurrence of hair loss during chemotherapy.

Hair loss is diffuse and non-scarring. It begins approximately 1-2 months after beginning chemotherapy. Around 10% of hairs are unaffected initially as that percentage are in a resting phase. If the chemotherapy is prolonged, total hair loss may follow. Alopecia is more common and more severe with combination chemotherapy.

The use of thiotepa is associated with permanent hair loss.

RegionalDerm

Homepage | Who is Dr. White? | Privacy Policy | FAQs | Use of Images | Contact Dr. White


It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.